Lulu Lv

Tianjin, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.

Journal: The New England journal of medicine

Published: January 14, 2026

Anti-CD19 CAR T cell therapy for refractory SLE-ITP.

Anti-CD19 CAR T cell therapy for refractory SLE-ITP.

Journal: Med (New York, N.Y.)

Published: September 22, 2025

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.

Long-term outcomes of CNCT19 chimeric antigen receptor T-cell therapy in relapsed or refractory aggressive B-cell lymphoma.

Journal: Chinese medical journal

Published: May 06, 2025

Anti-CD19 chimeric antigen receptor T cell therapy achieved rapid and sustained remission in a patient with systemic lupus erythematosus-associated refractory immune thrombocytopenia.

Anti-CD19 chimeric antigen receptor T cell therapy achieved rapid and sustained remission in a patient with systemic lupus erythematosus-associated refractory immune thrombocytopenia.

Journal: Clinical and experimental rheumatology

Published: April 08, 2025

Anti-CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE.

Anti-CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE.

Journal: The New England journal of medicine

Published: July 24, 2024

Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia.

Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia.

Journal: Blood advances

Published: July 10, 2024

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma.

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma.

Journal: Journal for immunotherapy of cancer

Published: March 25, 2024

A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.

A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.

Journal: Experimental hematology & oncology

Published: December 24, 2021

Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy.

Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy.

Journal: British journal of haematology

Published: May 12, 2020

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.

Journal: Journal of hematology & oncology

Published: May 04, 2020

Showing 1-10 of 10

Last Updated: 09/26/2026